1. Home
  2. CPT vs CYTK Comparison

CPT vs CYTK Comparison

Compare CPT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden Property Trust

CPT

Camden Property Trust

HOLD

Current Price

$110.38

Market Cap

10.8B

Sector

Real Estate

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$80.14

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPT
CYTK
Founded
1993
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8B
10.7B
IPO Year
1995
2004

Fundamental Metrics

Financial Performance
Metric
CPT
CYTK
Price
$110.38
$80.14
Analyst Decision
Buy
Strong Buy
Analyst Count
17
19
Target Price
$115.28
$89.26
AVG Volume (30 Days)
1.2M
1.9M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
4.03%
N/A
EPS Growth
136.00
N/A
EPS
0.40
N/A
Revenue
$12,967,000.00
$13,368,000.00
Revenue This Year
N/A
$7.37
Revenue Next Year
$2.60
$310.19
P/E Ratio
$271.68
N/A
Revenue Growth
81.69
N/A
52 Week Low
$96.53
$32.63
52 Week High
$116.59
$80.80

Technical Indicators

Market Signals
Indicator
CPT
CYTK
Relative Strength Index (RSI) 52.91 66.18
Support Level $105.56 $59.07
Resistance Level $111.94 N/A
Average True Range (ATR) 2.50 3.05
MACD -0.61 0.91
Stochastic Oscillator 42.77 95.55

Price Performance

Historical Comparison
CPT
CYTK

About CPT Camden Property Trust

Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: